Intercept Pharma Shares Higher Following New Buy Rating, $465 Target From UBS
April 17, 2015 at 10:20 AM EDT
In a report published Friday, UBS analysts initiated coverage of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) with a Buy rating and a ...
